AbbVie Inc. stays a Strong Buy after a Q4 2025 earnings beat led by HUMIRA, plus growth in immunology and neuroscience. Click ...
AbbVie Inc. (NYSE:ABBV) Q4 2025 Earnings Call Transcript February 4, 2026 AbbVie Inc. beats earnings expectations. Reported ...
ABBV heads into Q4 earnings with Skyrizi and Rinvoq driving growth, Humira sales sliding, and shares trading at a discount to ...
Zacks.com on MSN
AbbVie Beats on Q4 Earnings, Stock Down Despite Upbeat '26 View
AbbVie Inc. ABBV reported fourth-quarter 2025 adjusted EPS of $2.71, which beat the Zacks Consensus Estimate of $2.66. The ...
Elevating CMS oversight operationalizes Any Willing Provider by mandating “reasonable and relevant” participation terms, ...
AbbVie Inc (ABBV) surpasses revenue expectations with strong sales in immunology and neuroscience, while addressing challenges in the competitive landscape.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results